Q-omics provides the consensus-scored MIR3125 profile across patient tissues and cancer cell-line models. MIR3125 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MIR3125 is differentially expressed in 6, with the highest sampling consensus in STAD. Additionally, MIR3125 RNA expression shows 15,176 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, STAD, and THYM as cancer lineages where MIR3125 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3125 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3125 survival associations across molecular data types. MIR3125 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3125 RNA expression–survival associations across cancer types. High MIR3125 expression shows unfavorable associations in COAD, LGG, ACC, STAD and CESC, but favorable associations in MESO. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for MIR3125 RNA expression.
This table summarizes MIR3125 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3125. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3125 shows lower tumor expression in KICH, KIRP and THCA and higher tumor expression in STAD, LIHC and CHOL. The STAD box plot shows higher MIR3125 RNA expression in tumor versus normal tissue (log2 FC = +0.623, t-test p = .003).
This table shows molecular features associated with MIR3125 in patient tissues and cancer cell lines. In patient samples, MIR3125 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
